SCHEMBL12202124

SCHEMBL12202124

O=C(O)C1=C2c3ccccc3C(=O)N2CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
SCN2A Q99250 1/20 0.40
POLB P06746 2/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 5/20 0.39
GAA P10253 3/20 0.38
HTT P42858 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 3/20 0.37
PKM P14618 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2516651 0.90 POLB (0.44) BCAT2NPC1RAB9AALDH1A1CA12
SCHEMBL12228125 0.81 CASP3 (0.43) BCAT2NPC1RAB9AALDH1A1POLB
SCHEMBL12202123 0.76 HDAC1 (0.50) HDAC6
SCHEMBL24429208 0.76 NPC1 (0.48) NPC1RAB9ACA12CA9POLB
SCHEMBL12202106 0.74 NPC1 (0.47) BCAT2NPC1RAB9APOLBTSHR
SCHEMBL2511903 0.73 CASP3 (0.42) ALDH1A1POLBKMT2AHTTHSD17B10
SCHEMBL12202083 0.70 CASP3 (0.45) ALDH1A1KMT2AGAAHSD17B10MEN1
SCHEMBL12202091 0.68 NPC1 (0.45) NPC1RAB9AALDH1A1POLBTSHR
SCHEMBL12202114 0.67 NPC1 (0.38) BCAT2NPC1RAB9AALDH1A1TSHR
SCHEMBL31026166 0.67 CA12 (0.47) ALDH1A1CA12CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034939-B2 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases AVENTIS PHARMA S.A.. (FR) 2011-10-11 US disclosed
US-20080119507-A1 Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities AVENTIS PHARMA S.A. (FR) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119507-A1 Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities HSP90B1, HSP90AB2P, HSP90AB1 BCAT2 2164/4885NPC1 1045/4885RAB9A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.